Thu Sep 26 14:00:00 UTC 2024: ## New Research Identifies TBKBP1 as a Key Amplifier of Cytotoxic Activity in CMV-Specific T Cells

**Braunschweig, Germany – September 26, 2024** – A new study published in PLOS Pathogens identifies the gene TBKBP1 as a crucial regulator of the cytotoxic activity of human cytomegalovirus (CMV)-specific CD8+ T cells. This discovery has significant implications for understanding and potentially improving adoptive T cell therapies for CMV infections.

Researchers from the Helmholtz Centre for Infection Research and collaborating institutions conducted a comprehensive analysis of DNA methylation patterns in CMV-specific CD8+ T cells, also known as T(CMV) cells. They compared these patterns to those found in memory CD8+ T cells (Tmem) and naive CD8+ T cells (TN). Their findings revealed a unique epigenetic signature in T(CMV) cells, including a demethylated region in the TBKBP1 gene.

TBKBP1 is an adaptor protein known to interact with and activate the kinase TBK1, a central player in innate immune responses. This study demonstrates for the first time that TBKBP1 plays a significant role in adaptive T cell responses, specifically enhancing the cytotoxic activity of T(CMV) cells.

Further experiments showed that higher expression of TBKBP1 in T(CMV) cells correlated with increased phosphorylation of TBK1 upon stimulation. This suggests that TBKBP1 promotes the activation of TBK1 and its downstream signaling pathways, ultimately leading to enhanced antiviral responses.

The researchers also found that overexpression of TBKBP1 in CD8+ T cells resulted in increased production of pro-inflammatory cytokines and chemokines, further contributing to their enhanced virus neutralization capacity.

This research highlights the critical role of TBKBP1 in modulating CMV-specific T cell responses and suggests its potential as a therapeutic target for improving adoptive T cell therapies. By manipulating TBKBP1 expression or activity, researchers may be able to enhance the effectiveness of these therapies and provide better treatment options for CMV infections in immunocompromised individuals.

Read More